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t(4;11) MLL-AF4 pro-B acute lymphoblastic leukemia (ALL) is an aggressive hematological malignancy that accounts for 50-85% of infant ALL cases. 1 Retrospective analysis of Guthrie cards and twin concordance studies both confirmed the pre-natal origin of this disease. 2 Patients show an accumulation of immature pro-B cells in the bone marrow, followed by a rapid and uncontrolled proliferation of leukemia blasts that hijack the immune system and invade peripheral organs such as the spleen, liver and central nervous system. The chromosomal translocation results in the fusion of the N-terminal part of MLL with almost the entire AF4 gene, which disrupts the epigenetic signature of hematopoietic cells. 3 This induces a stem cell-like expression signature (e.g. HOXA cluster, MEIS1, RUNX1) as well as a pro-survival and proliferation phenotype (characterized by the upregulation of BCL2, MCL1, CDK6). [4] [5] [6] [7] [8] The molecular signature at diagnosis has been well characterized, but information on the initial changes during the first stages of leukemogenesis is lacking due to the challenge posed by the pre-natal origin of the disease. We recently described a pre-leukemia model of t(4;11) MLL-AF4 infant leukemia, which uses an Mll-AF4 invertor line and a VE-Cadherin-driven Cre recombinase to target the expression of Mll-AF4 to all definitive hematopoietic cells formed during embryonic development. 9 While this model does not progress to the same rapid, acute leukemia phenotype observed in human patients, possibly due to species differences, 10 it provides unique access to the prenatal pre-leukemic state in vivo. Mll-AF4 expression was shown to lead to increased engraftment and self-renewal potential of E14 fetal liver (FL) cells, as well as a high B lymphoid clonogenic potential; however, the precise contribution from individual cell types was not addressed in detail.
Here, we separated the hematopoietic compartment into three stem/progenitor fractions, HSC/MPPs, LMPPs and LK/CLPs, with a sorting strategy adapted to the fetal context ( Figure S1A ), 11 and used transplantation assays and gene expression analysis to further characterize the cell-of-origin of t(4;11) MLL-AF4 pro-B ALL.
Extensive details on the material and methods can be found in the supplementary section. Analysis of cell cycle distribution showed that the HSC/MPP population was more highly represented in the G0-G1 phase compared to LMPP and LK/CLP ( Figure   S1B ), and less in the G2/M phase ( Figure S1C ). Mll-AF4 did not alter the cell cycle distribution of HSC/MPPs, LMPPs or LK/CLPs, suggesting that proliferation is not hijacked during early stages of leukemogenesis.
All three fractions were transplanted to assess their engraftment, self-renewal and differentiation potentials. Mll-AF4 did not affect the engraftment of HSC/MPPs or LK/CLPs, but led to a significantly higher engraftment of the LMPP fraction ( Figure 1A -C). We previously found that HSC/MPPs and LMPPs from E14 FL could form Blymphoid colonies with a pro-B phenotype when Mll-AF4 is expressed. 9 We therefore assessed the lineage output in the peripheral blood of the primary recipients. While there was no difference in T (CD3+) and mature B cell (B220+CD19+IgM+) production, LMPPs had a lower myeloid (CD11b+Gr1+) and higher immature B cell (B220+CD19+IgM-) output compared with HSC/MPPs ( Figure 1D ). This skewing was, however, independent of Mll-AF4 expression and therefore represents an intrinsic property of LMPPs. Mll-AF4+ LMPP primary recipients had the highest white blood cell count one month after transplant, suggesting a faster contribution to the hematopoietic system ( Figure 1E To explain the cell type-specific effects, we assessed the expression of 14 genes associated with t(4;11) MLL-AF4 pro-B ALL and, more specifically, linked to HSC signature, B-lymphoid differentiation, cell division and pro-survival phenotypes: (Figure 2A Figure 1H ).
We observed a significant upregulation of Bcl-2 in Mll-AF4+ LMPPs compared to Mll-AF4-LMPPs ( Figure 2M ), which is a direct transcriptional target of MLL-AF4. 7 Mcl1 expression was relatively stable (Figure 2N 
Early stages of t(4;11) MLL-AF4 infant leukemia based on the pre-leukemia mouse model. A non-parametric Mann-Whitney test was used to compare datasets with a significance cut-off of p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) or p < 0.0001 (****).
Supplementary Material and Methods

Mice
The animal work was done under regulation of the UK Home Office. Males and females from the Mll-AF4 1 and the VEC-Cre 2 line were mated to obtain Mll-AF4-expressing embryos. The day of the plug was counted as day 0 of embryonic development.
Cell sorting of HSC/MPP, LMPP and LK/CLP populations
The fetal liver was dissected and dissociated in Flow Cytometry Staining Buffer 
